Clinical Trial Update: Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update discusses safety and efficacy of combining APL-101 with frontline Osimertinib in patients with EGFR-mutated metastatic non-small cell lu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• APL-101
• Osimertinib (osimertinib)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Metastatic Non Small Cell Lung Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING